Registry evaluating the impact of genomic testing on treatment of prostate cancer patients

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses the interim analysis of PROCEDEāˆ’1000, a prospective registry evaluating the impact of ProlarisĀ®, a cell cycle progression (CCP) test, on personalising treatment decisions following biopsy in newly diagnosed patients with prostate cancer.

Year of Production:
Running Time:
Color/Sound:

2015
01:39
Color/Sound

Comments are closed.